Skip to main content

Table 5 RAND SF-36 changes in scores

From: Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis

  Baseline to 1 month (N = 20) Baseline to 1 year (N = 17)
Better Same Worse Better Same Worse
Physical functioning 7 (35%) 4 (20%) 9 (45%) 10 (59%) 1 (6%) 6 (35%)
Role limitations—physicala 13 (65%) 6 (30%) 1 (5%) 11 (65%) 4 (24%) 2 (12%)
Role limitations—emotional 7 (35%) 10 (50%) 3 (15%) 5 (29%) 9 (53%) 3 (18%)
Energy/fatigueb 16 (80%) 1 (5%) 3 (15%) 11 (65%) 0 (0%) 6 (35%)
Emotional well-being 13 (65%) 2 (10%) 5 (25%) 10 (59%) 2 (12%) 5 (29%)
Social functioning 12 (60%) 2 (10%) 6 (30%) 8 (47%) 1 (6%) 8 (47%)
Pain 9 (45%) 5 (25%) 6 (30%) 6 (35%) 8 (47%) 3 (18%)
General health 11 (55%) 1 (5%) 8 (40%) 9 (53%) 2 (12%) 6 (35%)
Health changea 13 (65%) 6 (30%) 1 (5%) 11 (65%) 4 (24%) 2 (12%)
  1. aDifferences between baseline and 1-month and 1-year scores statistically significant (p < 0.03)
  2. bDifferences between baseline and 1-month scores statistically significant (p < 0.001)